<DOC>
	<DOCNO>NCT00541346</DOCNO>
	<brief_summary>This open-label study efficacy Daytrana ( methylphenidate transdermal system ) treatment attention behavioral symptom child Autism Spectrum Disorders . Twenty patient enrol treated 10-30 mg Daytrana total eight week . Changes core hyperactivity , impulsivity , inattention symptom , autism spectrum symptom functional outcome assess . Acceptability transdermal route administration population also assess . The researcher hypothesize Daytrana safe effective medication child Autism Spectrum Disorders symptom inattention , hyperactivity impulsivity .</brief_summary>
	<brief_title>A Pilot Study Daytrana TM Children With Autism Co-Morbid Attention Deficit Hyperactivity Disorder ( ADHD ) Symptoms</brief_title>
	<detailed_description>The design open-label trial eight week duration 20 child Autism co-morbid ADHD . The subject receive 7 day 10 mg Daytrana . The child see weekly assessment 4 week every two week eight week period complete . After week treatment , response reassess dose increase stepwise 15 mg , 20 mg , 30 mg unless excessive side effect , case , dose reduce previous dose patch wear time may revise .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Between 6 11 year Autism Spectrum Disorder Attention Deficit Hyperactivity Disorder Stimulant medicationfree study entry No clinically significant abnormality preclude safe participation Sufficient developmental level ( ~3 yrs ) Able keep appointment Able communicate effectively Teacher cooperation Received investigational medication previous 30 day Current medication treatment effective welltolerated Medical condition affect patient safety MAOIs within one month Hypertension Bipolar disorder psychosis Anticonvulsants Psychotropic medication health food supplement Tourette Disorder Seizure disorder Neurological condition Structural heart disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Autism</keyword>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>ADHD</keyword>
</DOC>